Effect of the antioxidant TK 12627 (Irganox) on monodeiodination and on the levels of messenger ribonucleic acid of 5′-deiodinase type I and spot 14
Until now, most potent inhibitors of monodeiodination are iodinated, propylthiouracil being an exception. We report here studies on a new non-iodinated substance, triethylene glycol bis-3-(3-tertbutyl-4-hydroxy-5-methyl-phenyl) propionate (TK 12627 or Irganox), which is used as a very efficient antioxidant in the chemistry of plastics. The studies were performed with 23 hypothyroid rats that received Irganox in their daily food (8 mg·day−1·(100 g body wt)−1) for 3 weeks. Thyroxine (T4) metabolism was studied by implanting minipumps delivering 2.3 nmol T4·dayℒ1·(100 g body wt)ℒ1 for 1 week. On day 1 before sacrifice, another minipump containing [125I]-3,5,3′-triiodothyronine (T3, 2.6 μCi/day) and [131I]-3,3′,5′-triiodothyronine (rT3, 2.1 μCi/day) was implanted. The results showed that with Irganox treatment serum T4 concentrations were higher (p<0.05). Serum T3 concentrations markedly decreased (1.07±0.07 vs 0.65±0.04 nmol/l), accompanied by a decrease of free T3 concentrations (p<0.001). Serum rT3 concentrations increased by 50% (p<0.001). Serum thyrotropin levels were mostly unmeasurable. The plasma clearance rate decreased slightly for T4 (19%, p<0.05) and remarkably for rT3 (46.7%, p<0.001). The conversion rate of T4 to rT3 did not change. Deiodinase type I (5′D-I) activity decreased in both liver and kidney tissues by 54% and 52%, respectively, and correlated with T3 (r2 = 0.79 and 0.65, respectively). Brain deiodinase type III (5D-III) was unchanged and type II (5′D-II) was unmeasurable. The relative abundance of 5′D-I messenger ribonucleic acid (mRNA) levels decreased by 40% in liver and 42% in kidney and it correlated with serum T3 levels also (r2 = 0.71 and 0.72, respectively). The amount of hepatic spot 14 mRNA also decreased by 41% (p<0.05); however, the abundance of hepatic beta-actin mRNA was not affected by the treatment. In an additional experiment. Irganox-treated rats received 2 nmol T3 ·day−1·(100 g body wt)−1; this treatment prevented the changes in mRNA levels of 5′D-I and spot 14 but did not prevent the decrease of 5′D-I activity in either liver or kidney. In vitro studies with liver microsomes showed that Irganox is a specific non-competitive inhibitor of 5′D-I activity, with a Ki of 12 μmol/l. These studies suggest that Irganox, by inhibiting 5′D-I activity, can effect thyroid hormone monodeiodination followed by changes of mRNA levels of some thyroid hormone-dependent target genes.